Referred to the House Committee on Energy and Commerce.
This bill amends the Federal Food, Drug, and Cosmetic Act to require a physical chemical identifier on each dose of certain pharmaceuticals. Specifically, controlled substances in solid oral dosage form manufactured five years after enactment must include a machine-readable physical chemical identifier.
Public-safety benefits versus regulatory cost burden on industry.
Narrow, safety‑oriented change likely to attract bipartisan support, though industry cost concerns could generate opposition.
This bill amends the Federal Food, Drug, and Cosmetic Act to require a physical chemical identifier on each dose of certain pharmaceuticals.
Specifically, controlled substances in solid oral dosage form manufactured five years after enactment must include a machine-readable physical chemical identifier.
The statutory definitions of "product identifier" and "verification" are expanded to permit either the existing standardized graphic or a physical chemical identifier, and to allow authenticity verification using such chemical identifiers.
Technically focused, safety‑oriented proposal with transitional timing; implementation costs and rulemaking needs lower but not negligible chance barriers.
How solid the drafting looks.
Public-safety benefits versus regulatory cost burden on industry.
These are examples from the analysis, not a ranked list of the most-affected groups.
Public-safety benefits versus regulatory cost burden on industry.
Likely supportive because the measure targets counterfeit and diverted controlled substances and strengthens patient safety.
They will welcome technological approaches to authenticate pills, but worry about costs being passed to patients and unequal impacts on smaller manufacturers.
Generally favorable if the bill includes clear standards, reasonable timelines, and cost controls.
They will emphasize pragmatic implementation, measurable benefits, and avoiding large regulatory surprises that create shortages or high costs.
Cautious to skeptical: supportive of anti-counterfeiting goals but concerned about federal regulatory expansion and industry burden.
They will press for minimal federal intrusion, cost containment, and protection for smaller firms and competition.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically focused, safety‑oriented proposal with transitional timing; implementation costs and rulemaking needs lower but not negligible chance barriers.
The bill has not accumulated any surfaced votes yet.
Public-safety benefits versus regulatory cost burden on industry.
Technically focused, safety‑oriented proposal with transitional timing; implementation costs and rulemaking needs lower but not negligible…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Modern Authentication of Pharmaceuticals Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.